Journal article
Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation
HTH Tu, BCV Campbell, L Churilov, JM Kalman, KR Lees, PD Lyden, A Shuaib, GA Donnan, SM Davis
Cerebrovascular Diseases | KARGER | Published : 2011
DOI: 10.1159/000332028
Abstract
Background: Atrial fibrillation (AF) is associated with worse outcomes following ischemic stroke and more frequent cardiac complications in the general population. We aimed to establish whether early cardiac complications contribute to the poorer ischemic stroke outcomes in patients with AF, independent of baseline differences in age, stroke severity and cardiovascular risk factors. This might have important implications for acute stroke management in patients with AF. Methods: We searched VISTA-Acute, an academic database containing standardized data for 28,131 patients from 30 randomized-controlled acute stroke trials and 1 stroke registry, for imaging-confirmed placebo-treated patients wi..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
This study received funding from The Royal Melbourne Hospital Neuroscience Foundation.H.T.H. Tu, B. C. V. Campbell, L. Churilov and J.M. Kalman report no relevant disclosures. K. R. Lees has received honoraria from Astellas, Asubio, Bayer, Boehringer Ingelheim, Johnson & Johnson, Lundbeck, Mitsubishi, Photothera, Sanofi-Aventis, Servier, Talecris, and Wyeth. P. D. Lyden receives royalties from sale of the book Thrombolytic Therapy for Acute Stroke. A. Shuaib has received honoraria and research grants from Astra Zeneca, Boehringer Ingelheim, Pfizer, Roche, Bayer, Coaxia, and Photothera. G. A. Donnan has served on advisory boards for Boehringer Ingelheim, Servier, Sanofi-Aventis and Bristol Myers Squibb. S. M. Davis has served on advisory Boards for Boehringer Ingelheim, Ever Pharma, Pfizer and Sanofi-Aventis.